(Q35134373)

6 August 2017

1 reference

title

Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers (English)

1 reference

6 August 2017

0 references

0 references

0 references

3

Kaj Blennow

1 reference

6 August 2017

1

Magnus Sjögren

1 reference

6 August 2017

Niels Andreasen

2

1 reference

6 August 2017

1 June 2003

1 reference

6 August 2017

1 reference

6 August 2017

332

1 reference

6 August 2017

1-2

1 reference

6 August 2017

1-10

1 reference

Amyloid beta protein 1-42/43 (A beta 1-42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Clinical-neuropathological correlations in Alzheimer's disease and related dementias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Tau protein and the neurofibrillary pathology of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Axonal degeneration promotes abnormal accumulation of amyloid beta-protein in ascending gracile tract of gracile axonal dystrophy (GAD) mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Microtubule formation and neurite growth in cerebellar macroneurons which develop in vitro: evidence for the involvement of the microtubule-associated proteins, MAP-1a, HMW-MAP2 and Tau

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Mechanism of Alzheimer neurofibrillary degeneration and the formation of tangles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Both total and phosphorylated tau are increased in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Cerebrospinal protein tau is elevated in early Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

Increased numbers of beta APP-immunoreactive neurones in the entorhinal cortex after head injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2803%2900121-9

10.1016/S0009-8981(03)00121-9

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12763273